FDA-cleared profile

SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.

Clinical role
CT patient positioning and acquisition, image reconstruction, image evaluation, and optional post-processing support within diagnosis, treatment planning, radiation therapy planning, and intervention workflows.
Images and patients
CT/CTA · Whole body
Key limitation
Keep in mind: The CT systems are not the principal means of guidance during invasive procedures, and needle orientation and advancement remain under physician control. Optional advanced-visualization applications require their own cleared standalone version, and feature availability varies across scanner models and configurations.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Whole body Input: X-ray transmission data acquired on the listed SOMATOM go and SOMATOM X single-source CT scanner systems; supported options include three-dimensional camera data for patient positioning and external respiratory trigger signals for specified workflows.
  • Who uses it?Intended users: Trained and qualified users in professional healthcare facilities, including physicians, radiologists, and technologists; diagnosis or treatment requires appropriately qualified U.S. users.
  • What does the software produce?Output: Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.
  • What is its most important limitation?Key limitation: The CT systems are not the principal means of guidance during invasive procedures, and needle orientation and advancement remain under physician control. Optional advanced-visualization applications require their own cleared standalone version, and feature availability varies across scanner models and configurations.

Clinical takeaway. Clinical role: The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.

Evidence takeaway. Evidence from the reviewed source record: FDA-reviewed support consists of non-clinical integration, functional, image-quality, phantom, and bench testing for the listed CT platforms with syngo CT VB10. The 510(k) summary does not describe an independent clinical outcomes study.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
CT patient positioning and acquisition, image reconstruction, image evaluation, and optional post-processing support within diagnosis, treatment planning, radiation therapy planning, and intervention workflows.
  • Exact FDA submission
  • Checked 2026-09-02
Required input
X-ray transmission data acquired on the listed SOMATOM go and SOMATOM X single-source CT scanner systems; supported options include three-dimensional camera data for patient positioning and external respiratory trigger signals for specified workflows.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Professional healthcare facilities.
  • Exact FDA submission
  • Checked 2026-09-02
Intended users
Trained and qualified users in professional healthcare facilities, including physicians, radiologists, and technologists; diagnosis or treatment requires appropriately qualified U.S. users.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
The CT systems are not the principal means of guidance during invasive procedures, and needle orientation and advancement remain under physician control. Optional advanced-visualization applications require their own cleared standalone version, and feature availability varies across scanner models and configurations.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
FDA-reviewed support consists of non-clinical integration, functional, image-quality, phantom, and bench testing for the listed CT platforms with syngo CT VB10. The 510(k) summary does not describe an independent clinical outcomes study.
  • Exact FDA submission
  • Checked 2026-09-02

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA-reviewed support consists of non-clinical integration, functional, image-quality, phantom, and bench testing for the listed CT platforms with syngo CT VB10. The 510(k) summary does not describe an independent clinical outcomes study.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Automatic needle-tip detection

90.76 % of tested cases

  • EndpointCases in which the myNeedle Guide automatic needle-detection algorithm consistently detected the needle tip
  • PopulationA wide variety of CT scans used in manufacturer bench testing; sample size and clinical case composition were not reported in the 510(k) summary
  • Tested versionmyNeedle Guide with myNeedle Detection on supported K233650 systems with SOMARIS/10 syngo CT VB10

K233650 non-clinical performance testing

  • DesignManufacturer integration, functional, image-quality, phantom, and feature-specific bench verification and validation
  • PopulationSOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10
  • Scopeexact submission
  • Tested versionSOMARIS/10 syngo CT VB10
  • IndependenceSponsor or vendor study

K233650

Regulatory non-clinical evidence; it does not establish comparative clinical outcomes or site-specific performance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
FDA recall Z-1239-2026 affects syngo.CT Brain Quantification, Vessel Hyperdensities, and ASPECTS applications on certain SOMATOM X.ceed systems. The FDA record states that the applications had not received 510(k) clearance, directs sites to stop using them in patient care, and says Siemens would remove them. FDA lists the recall as open and classified.
  • FDA source
  • Exact product version
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-1239-2026

Open, Classified

2026-02-03

Exact SOMATOM X.ceed application match. The finding applies to the named applications and affected installations, not every function of the scanner platform.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray transmission data acquired on the listed SOMATOM go and SOMATOM X single-source CT scanner systems; supported options include three-dimensional camera data for patient positioning and external respiratory trigger signals for specified workflows.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K233650: SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

  2. Routing

    Source context, not route validation: The platform produces DICOM images and provides software interfaces for compatible optional post-processing applications, including previously cleared Siemens applications and other commercially distributed software.

    Scope: Exact FDA submission. Confirm PACS routing, DICOM object support, interface versions, and each optional application's clearance and compatibility for the planned local configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-02 · FDA K233650: SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

  3. AI processing

    Source context, not route validation: On-premises SOMATOM go or SOMATOM X scanner and computer platform running SOMARIS/10 syngo CT VB10, supplied ex-factory or as an optional upgrade for applicable existing systems.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-02 · FDA K233650: SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

  4. Returned objects

    Source context, not route validation: Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K233650: SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

  5. Viewer/worklist/report

    Unresolved route: Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K233650: SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
On-premises SOMATOM go or SOMATOM X scanner and computer platform running SOMARIS/10 syngo CT VB10, supplied ex-factory or as an optional upgrade for applicable existing systems.
  • Exact FDA submission
  • Checked 2026-09-02
Integration
The platform produces DICOM images and provides software interfaces for compatible optional post-processing applications, including previously cleared Siemens applications and other commercially distributed software.
  • Exact FDA submission
  • Checked 2026-09-02

Confirm PACS routing, DICOM object support, interface versions, and each optional application's clearance and compatibility for the planned local configuration.

Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Monitoring
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Supported platforms and version

SOMATOM go.Up, go.Now, go.All, go.Top, go.Sim, go.Open Pro, X.cite, and X.ceed with SOMARIS/10 syngo CT VB10.

exact submission · checked 2026-09-02

Feature availability differs by scanner model; verify the exact purchased and installed configuration.

DICOM and post-processing

Produces CT images in DICOM format and supports compatible optional post-processing applications through platform software interfaces.

exact submission · checked 2026-09-02

Confirm local PACS routing, supported DICOM objects, and the clearance and version compatibility of each optional application.

Deployment model

On-premises scanner and computer platform; syngo CT VB10 may be supplied with a new system or as an upgrade to an applicable installed system.

exact submission · checked 2026-09-02

Site preparation, upgrade eligibility, downtime, validation, cybersecurity hardening, and service terms require current vendor documentation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233650
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact device classification names the subject device as a Computed Tomography X-ray System. Controlled directory normalization: Computed Tomography X-ray System -> CT/CTA.

Anatomy
Whole body
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact technical-characteristics section identifies the scanner principle as a Whole body X-Ray Computed Tomography Scanner; no narrower anatomy is inferred.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-03-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
22Fields reviewed
9Source classes checked
4Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission

    No public price or quote for the exact K233650 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Siemens SOMATOM go reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K233650: SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed

    U.S. Food and Drug Administration - Published 2024-03-26 - Accessed 2026-09-19

    Scope: purpose, intendedUsers, input, output, limitations, modality, anatomy, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-1239-2026: SOMATOM X.ceed Software applications: syngo.CT Brain Quantification syngo.CT Vessel Hyperdensities syngo.CT ASPECTS

    U.S. Food and Drug Administration - Published 2026-02-03 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K233650 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253560

Enhanced Boundary for PCCT

Ge Medical Systems, LLC

Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.

Modality
CT/CTA
Anatomy
Head
Decision
2026-06-24
FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K252041

Fibresolve (with PCCP)

Imvaria, Inc.

Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.

Modality
CT/CTA
Anatomy
Lungs and interstitial lung disease patterns
Decision
2025-11-07

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history